Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

The OVAL study for VB-111 treatment of platinum-resistant ovarian cancer

Obiettivo

VBL therapeutics is a late-stage clinical biopharmaceutical company focused on first in class treatments for cancer. VBL's lead oncology product candidate, VB-111, is an innovative targeted anti-cancer gene therapy with potential to treat a wide range of solid tumors. Most cancer therapies aim to target tumors cells while sparing normal cells, but tumors are heterogeneous and often develop resistance to treatment. Instead of targeting the tumor directly, VB-111 targets the tumor environment by disrupting the blood vessels that supply blood to the tumor and by recruiting the immune system into the tumor. This dual mechanism of action together with an excellent safety profile make VB-111 a game-changer. VBL is pursuing Ovarian Cancer as the first indication for VB-111. In the scope of this project, VBL will to finalize a Phase 3 potential-registration clinical trial, the OVAL study as well as execute all the necessary steps towards final regulatory approvals and commercialization

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2021-ACCELERATOROPEN-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

VASCULAR BIOGENICS LTD
Contributo netto dell'UE
€ 2 500 000,00
Indirizzo
8 HASATAT STREET
7178106 MODIIN
Israele
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 7 037 500,00